Bon Vivant, a France-based alternative dairy startup has signed a strategic partnership with Abolis Biotechnologies, a European specialist in synthetic biology.
Through the partnership, the two companies will pool their expertise and technology to produce milk proteins via precision fermentation on a large scale for use in the dairy industry.
<ul><li> Analyst QuickTake: Bon Vivant is well on its way to commercialization. This partnership comes just two months after the company raised EUR 4 million (~USD 4.3 million) in April 2022. The partnership with a European biotech leader could allow the company to attract more significant investors in the future, allowing it to accelerate the commercialization of its products while tapping into other European markets beyond France.</ul>
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.